Epidermal growth factor receptor tyrosine kinase inhibitor in treatment of elderly patients with nonsmall-cell lung cancer / 中华全科医师杂志
Chinese Journal of General Practitioners
;
(6): 221-223, 2012.
Article
in Chinese
| WPRIM
| ID: wpr-424778
ABSTRACT
Seventy patients with advanced non-small-cell lung cancer (NSCLC) aged 65 or above were treated with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib or gefitinib from February 2006 to September 2010. The efficacy and toxicities of treatment were retrospectively analyzed.The overall response rate and disease control rate were 31.4% and 84.3%,respectively. Themedian progression-free survival time and median survival time were 8.0 months and 13.5 months,respectively(P < 0.05 ). One-year survival rate was 54.3%. Response rate ( CR + PR) ( 42.9% ) anddisease control rate (94.3% )in female patients were superior to males (20.0% and 74.3% ) (P < 0.05 ).Non-smoking and PS score < 2 were good predictors for survival.The side effects were generally mild and mainly were skin rash and diarrhea.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Chinese Journal of General Practitioners
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS